TY - CHAP M1 - Book, Section TI - Major Vaccine-Preventable Viral Infections A1 - Akamine, Christine A1 - Clark, Eva A1 - Shandera, Wayne X. A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. PY - 2023 T2 - Current Medical Diagnosis & Treatment 2023 AB - Key Clinical Updates in Major Vaccine-Preventable Viral InfectionsA novel oral polio vaccine type 2 (nOPV2) has been developed in response to the ongoing circulating vaccine-derived type 2 poliovirus outbreaks and has been shown to be safe and immunogenic in previously immunized adults. Studies have shown that nOPV2 is more genetically stable than the mOPV2 and therefore less prone to reverting to neurovirulence. The nOPV2 was recommended for initial use under the World Health Organization’s Emergency Use Listing Procedure in November 2020.Coster ID et al. Lancet. [PMID: 33308429] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193135139 ER -